专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US12083227B2 Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis 有权
公开(公告)号：US12083227B2
公开(公告)日：2024-09-10
申请号：US16105440
申请日：2018-08-20
申请人： AbbVie Inc. , Neurocrine Biosciences, Inc.
发明人： Yihong Qiu , Yuchuan Gong , Alexander Ruggles , Jared A. Baird , Hui Zu , Gregory A. McClelland , Anna V. Stepanenko
IPC分类号： A61K9/20 , A61K31/513 , A61P15/00
CPC分类号： A61K9/2031 , A61K9/2009 , A61K9/2013 , A61K9/2027 , A61K31/513 , A61P15/00
摘要： The present disclosure relates to pharmaceutical compositions comprising a gonadotropin-releasing hormone (GnRH) antagonist and methods of preparing and using such compositions. The disclosure also relates to methods of facilitating release of a GnRH antagonist from a pharmaceutical composition.

2. 发明申请

US20150126574A1 ATRASENTAN MANDELATE SALTS 有权
标题翻译： ATRASANAN MANDELATE SALTS
公开(公告)号：US20150126574A1
公开(公告)日：2015-05-07
申请号：US14594742
申请日：2015-01-12
申请人： AbbVie Inc.
发明人： Yuchuan Gong , Geoff G. Zhang
IPC分类号： C07D405/04 , C07C59/54
CPC分类号： C07D405/04 , C07B2200/07 , C07B2200/13 , C07C59/50 , C07C59/54
摘要： The present disclosure relates to: (a) mandelate salts of atrasentan, (b) pharmaceutical compositions comprising an atrasentan mandelate salt, and, optionally, one or more additional therapeutic agents; (b) methods of using an atrasentan mandelate salt to treat nephropathy, chronic kidney disease, and/or other conditions; (c) kits comprising a first pharmaceutical composition comprising an atrasentan mandelate salt, and, optionally, a second pharmaceutical composition comprising one or more additional therapeutic agents; (d) methods for the preparation of an atrasentan mandelate salt; and (e) atrasentan mandelate salts prepared by such method.
摘要翻译：本公开内容涉及：（a）阿替司坦的扁桃酸盐，（b）药物组合物，其包含盐酸阿斯替康和任选的一种或多种另外的治疗剂; （b）使用阿坦替兰扁桃酸盐治疗肾病，慢性肾脏疾病和/或其他病症的方法; （c）试剂盒，其包含第一药物组合物，所述药物组合物包含阿替立森扁桃酸盐和任选的包含一种或多种另外的治疗剂的第二药物组合物; （d）制备盐酸阿特拉斯坦的方法; 和（e）通过这种方法制备的扁桃酸盐。

3. 发明公开

US20230312566A1 SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT 审中-公开
公开(公告)号：US20230312566A1
公开(公告)日：2023-10-05
申请号：US18047408
申请日：2022-10-18
申请人： AbbVie Inc.
发明人： Nathaniel Catron , Shuang Chen , Yuchuan Gong , Geoff G. Zhang
IPC分类号： C07D471/04 , A61P35/02
CPC分类号： C07D471/04 , A61P35/02
摘要： Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

4. 发明申请

US20200255425A1 SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT 审中-公开
公开(公告)号：US20200255425A1
公开(公告)日：2020-08-13
申请号：US16858278
申请日：2020-04-24
申请人： AbbVie Inc.
发明人： Nathaniel Catron , Shuang Chen , Yuchuan Gong , Geoff G. Zhang
IPC分类号： C07D471/04
摘要： Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

5. 发明授权

US10730873B2 Salts and crystalline forms of an apoptosis-inducing agent 有权
公开(公告)号：US10730873B2
公开(公告)日：2020-08-04
申请号：US15806964
申请日：2017-11-08
申请人： AbbVie Inc.
发明人： Nathaniel Catron , Shuang Chen , Yuchuan Gong , Geoff G. Zhang
IPC分类号： C07D471/04
摘要： Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

6. 发明授权

US09321765B2 Crystalline bromodomain inhibitors 有权
标题翻译：结晶溴结构域抑制剂
公开(公告)号：US09321765B2
公开(公告)日：2016-04-26
申请号：US14317029
申请日：2014-06-27
申请人： AbbVie Inc.
发明人： Yuchuan Gong
IPC分类号： C07D471/02 , A61K31/44 , C07D471/04
CPC分类号： C07D471/04 , C07B2200/13
摘要： N-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethanesulfonamide and crystalline forms thereof are suitable pharmaceutical ingredients for pharmaceutical compositions useful in the treatment of disease, for example, cancer.
摘要翻译： N- [4-（2,4-二氟苯氧基）-3-（6-甲基-7-氧代-6,7-二氢-1H-吡咯并[2,3-c]吡啶-4-基）苯基]乙磺酰胺和其结晶形式是用于治疗疾病例如癌症的药物组合物的合适的药物成分。

7. 发明授权

US08962675B1 Atrasentan mandelate salts 有权
标题翻译：阿特拉斯顿扁桃酸盐
公开(公告)号：US08962675B1
公开(公告)日：2015-02-24
申请号：US14133297
申请日：2013-12-18
申请人： AbbVie Inc.
发明人： Yuchuan Gong , Geoff G. Zhang
IPC分类号： A61K31/519 , C07D405/04 , C07C59/54
CPC分类号： C07D405/04 , C07B2200/07 , C07B2200/13 , C07C59/50 , C07C59/54
摘要： The present disclosure relates to: (a) mandelate salts of atrasentan, (b) pharmaceutical compositions comprising an atrasentan mandelate salt, and, optionally, one or more additional therapeutic agents; (b) methods of using an atrasentan mandelate salt to treat nephropathy, chronic kidney disease, and/or other conditions; (c) kits comprising a first pharmaceutical composition comprising an atrasentan mandelate salt, and, optionally, a second pharmaceutical composition comprising one or more additional therapeutic agents; (d) methods for the preparation of an atrasentan mandelate salt; and (e) atrasentan mandelate salts prepared by such method.
摘要翻译：本公开内容涉及：（a）阿替司坦的扁桃酸盐，（b）药物组合物，其包含盐酸阿斯替康和任选的一种或多种另外的治疗剂; （b）使用阿坦替兰扁桃酸盐治疗肾病，慢性肾脏疾病和/或其他病症的方法; （c）试剂盒，其包含第一药物组合物，所述药物组合物包含阿替立森扁桃酸盐和任选的包含一种或多种另外的治疗剂的第二药物组合物; （d）制备盐酸阿特拉斯坦的方法; 和（e）通过这种方法制备的扁桃酸盐。

8. 发明申请

US20170190692A1 ATRASENTAN MANDELATE SALTS 审中-公开
公开(公告)号：US20170190692A1
公开(公告)日：2017-07-06
申请号：US15464455
申请日：2017-03-21
申请人： AbbVie Inc.
发明人： Yuchuan Gong , Geoff G. Zhang
IPC分类号： C07D405/04 , C07C59/50
CPC分类号： C07D405/04 , C07B2200/07 , C07B2200/13 , C07C59/50 , C07C59/54
摘要： The present disclosure relates to: (a) mandelate salts of atrasentan, (b) pharmaceutical compositions comprising an atrasentan mandelate salt, and, optionally, one or more additional therapeutic agents; (b) methods of using an atrasentan mandelate salt to treat nephropathy, chronic kidney disease, and/or other conditions; (c) kits comprising a first pharmaceutical composition comprising an atrasentan mandelate salt, and, optionally, a second pharmaceutical composition comprising one or more additional therapeutic agents; (d) methods for the preparation of an atrasentan mandelate salt; and (e) atrasentan mandelate salts prepared by such method.

9. 发明授权

US09469673B2 Crystaline forms of HCV inhibitor 有权
标题翻译： HCV抑制剂的晶体形式
公开(公告)号：US09469673B2
公开(公告)日：2016-10-18
申请号：US13939873
申请日：2013-07-11
申请人： AbbVie Inc.
发明人： Ahmad Y. Sheikh , Moiz Diwan , Agnes E. Pal , Yuchuan Gong , Paul J. Brackemeyer , Geoff Zhang , Seble Wagaw
IPC分类号： C07K5/083 , C07K5/12 , C07D487/04
CPC分类号： C07K5/123 , C07D487/04 , C07K5/0804
摘要： The present invention features crystalline forms of Compound I. In one embodiment, a crystalline form of Compound I has characteristic peaks in the PXRD pattern at values of two theta (° 2θ) of 10.7, 11.6, 12.7, 13.0, 13.2, 13.7, 14.5, 18.7, 19.0, and 19.9 after equilibration at 43% relative humidity.
摘要翻译：本发明的特征在于化合物I的结晶形式。在一个实施方案中，化合物I的结晶形式在2θ（°2θ）为10.7,11.6,12.7,13.0,13.2,13.7,14.5的值的PXRD图中具有特征峰，18.7,19.0和19.9，在43％相对湿度下平衡后。

10. 发明申请

US20160083384A1 SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT 有权
标题翻译：病毒诱导剂的口服和结晶形式
公开(公告)号：US20160083384A1
公开(公告)日：2016-03-24
申请号：US14957097
申请日：2015-12-02
申请人： AbbVie Inc.
发明人： Nathaniel Catron , Shuang Chen , Yuchuan Gong , Geoff G. Zhang
IPC分类号： C07D471/04
CPC分类号： C07D471/04
摘要： Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
摘要翻译：盐酸盐和4-（4 - {[2-（4-氯苯基）-4,4-二甲基环己-1-烯-1-基]甲基}哌嗪-1-基）-N - （{3-硝基 -4 - [（四氢-2H-吡喃-4-基甲基）氨基]苯基} - 磺酰基）-2-（1H-吡咯并[2,3-b]吡啶-5-基氧基）苯甲酰胺是药物的合适的活性药物成分可用于治疗以一种或多种抗凋亡Bcl-2家族蛋白（例如癌症）过表达为特征的疾病的组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式